CN108619122A - Treat the pharmaceutical composition of premature ejaculation - Google Patents
Treat the pharmaceutical composition of premature ejaculation Download PDFInfo
- Publication number
- CN108619122A CN108619122A CN201710152275.0A CN201710152275A CN108619122A CN 108619122 A CN108619122 A CN 108619122A CN 201710152275 A CN201710152275 A CN 201710152275A CN 108619122 A CN108619122 A CN 108619122A
- Authority
- CN
- China
- Prior art keywords
- pargyline
- prozac
- pharmaceutical composition
- premature ejaculation
- officinal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
Abstract
The present invention relates to a kind of pharmaceutical compositions, disclose a kind of pharmaceutical composition for treating premature ejaculation.It includes as the Pargyline of active constituent or its officinal salt, Prozac or its officinal salt, wherein the Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be 0.1:10~10:0.1；Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be 1:10~10:1；The officinal salt is hydrochloride；It further include optional pharmaceutic adjuvant；Described pharmaceutical composition is oral preparation；The unit dosage forms of the oral preparation include the Prozac of the Pargyline of 0.1~10mg, 0.1~10mg；The unit dosage forms of the oral preparation include the Prozac of the Pargyline of 1~10mg, 1~10mg；The present invention has the advantages that medical at low cost, Small side effects.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions, specifically, being about a kind of pharmaceutical composition for treating premature ejaculation.
Background technology
Premature ejaculation is most common Ejaculatory dysfunction, and incidence accounts for 1/3 of man or more.The clinical manifestation master of premature ejaculation
If ejaculation is too fast, man is of short duration in contact or just contact wife's side vulva or time after erection, is not yet into climax
Ejaculation.The reason of causing premature ejaculation can be divided into premature ejaculation caused by psychological premature ejaculation, organic premature ejaculation and other reasons, wherein psychological
Premature ejaculation is the main reason for causing premature ejaculation.
Current oral drug therapy is one of the main method of premature ejaculation treatment, and oral drug therapy mainly uses 5- hydroxyl colors
Amine reuptaking inhibitor, what the country had listed is Dapoxetine hydrochloride, it mainly extends ejaculation latency, there is larger side effect,
And it is expensive.
Relevant industries need to treat the new medicine of premature ejaculation, with effective and excellent therapeutic effect, and can subtract
Small Nausea and vomiting, it is sleepy, etc. side effects；And drug price is relatively low, to reduce medical treatment cost, mitigates patient burden.
Invention content
The object of the present invention is to provide a kind of pharmaceutical compositions for treating premature ejaculation.
The present invention is achieved by the following technical solutions：The pharmaceutical composition of premature ejaculation is treated, including as active constituent
Pargyline or its officinal salt, Prozac or its officinal salt, wherein the Pargyline or its officinal salt, Prozac or
The weight ratio of its officinal salt is 0.1:10~10:0.1.
Preferably, the Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be 1:10~10:1.
Most preferably, the Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be 1:1.
Preferably, the officinal salt is hydrochloride.
The invention also includes optional pharmaceutic adjuvants.
Preferably, the pharmaceutic adjuvant includes excipient, disintegrant, adhesive, lubricant, emulsifier, suspending agent, stabilization
Agent, sweetener, flavoring agent.
Preferably, described pharmaceutical composition is oral preparation, including tablet, capsule, granule, pill.
Preferably, the unit dosage forms of the oral preparation include the Prozac of the Pargyline of 0.1~10mg, 0.1~10mg.
It is highly preferred that the unit dosage forms of the oral preparation include the Prozac of the Pargyline of 1~10mg, 1~10mg.
Most preferably, the unit dosage forms of the oral preparation include the Prozac of the Pargyline of 10mg, 10mg.
Compared with prior art, the beneficial effects of the invention are as follows：Present invention proportioning is reasonable, prepares simply, is conducive to industrialization
Production；The present invention can treat prospermia of males symptom, extend male's sexual life time；Medical treatment cost is reduced, patient is alleviated
Medical burden；The present invention does not have found fatefulue serotonin syndrome, reduces side effect when paying a return visit patient.
Specific implementation mode
The specific implementation mode of the present invention will be described in detail below, to more fully understand the present invention.
Inventor developed a kind of pharmaceutical compositions for treating premature ejaculation, and find to take orally the mixing of Pargyline, Prozac
Object can significantly treat premature ejaculation and reduce side effect.
A kind of pharmaceutical composition for treating premature ejaculation provided by the present invention include as the Pargyline of active constituent or its can
Pharmaceutical salts, Prozac or its officinal salt, wherein the Pargyline or its officinal salt, Prozac or its officinal salt weight
Amount is than being 0.1:10~10:0.1.
Preferably, the Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be 1:10~10:1.
Most preferably, the Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be 1:1.
Preferably, the officinal salt is hydrochloride.
The invention also includes optional pharmaceutic adjuvants.
Pharmaceutical composition provided by the invention is oral preparation.
Preferably, the unit dosage forms of the oral preparation include the Prozac of the Pargyline of 0.1~10mg, 0.1~10mg.
It is highly preferred that the unit dosage forms of the oral preparation include the Prozac of the Pargyline of 1~10mg, 1~10mg.
Most preferably, the unit dosage forms of the oral preparation include the Prozac of the Pargyline of 10mg, 10mg.
The Pargyline and Prozac refer to its respective free alkali form, and the amount generation of Pargyline and Prozac herein
The calculated value of each active constituent of the table based on free alkali form.
The Pargyline, Prozac officinal salt refer to the non-toxic salts in dosage, including conventional salt such as inorganic acid salt, having
Machine hydrochlorate or non-toxic salts.
The inorganic acid includes but not limited to hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid and phosphorous
Acid.The example of the organic acid includes acetic acid, lactic acid, citric acid, malic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, benzene
Formic acid, phthalic acid, gluconic acid, saccharinic acid, methanesulfonic acid, ethionic acid, aliphatic monocarboxylic acid ester/salt and dicarboxylic ester/salt,
Alkanoate/salt, hydroxy alkane acid ester/salt and chain docosandioic acid ester/salt, aromatic acid and the aliphatic and aromatic series sulphur of phenyl substitution
Acid.Preferred organic acid is hydrochloric acid/hydrochloride.
The non-toxic salts include but not limited to sulfate, pyrosulfite, disulfate, sulphite, bisulfite
Salt, nitrate, phosphate, hydrophosphate, dihydric phosphate, metaphosphate, pyrophosphate chloride, bromide, iodide, fluorine
Compound, acetate, propionate, caprate, caprylate, acrylates, formates, isobutyrate, caprate, enanthate, propine
Hydrochlorate, oxalates, malonate, succinate, suberate, sebacate, fumarate, maleate, butene-1,4- bis-
Hydrochlorate, hexane -1,6- diacid salt, benzoate, chloro-benzoate, methyl benzoic acid salt, dinitro-benzoate, hydroxy benzenes
Formates, methoxy benzoic acid salt, phthalate, terephthalate, benzene sulfonate, toluene fulfonate, chlorobenzenesulfonic acid
Salt, xylenesulfonate, phenylacetate, phenylpropionic acid salt, phenylbutyrate, citrate, lactate, beta-hydroxy-butanoic acid salt,
Oxyacetate, malate, tartrate, mesylate, propane sulfonic acid salt, naphthalene -1- sulfonate, naphthalene-2-sulfonic acid salt and mandelic acid
Salt.
Oral preparation described herein can be：Tablet, capsule, suspension, granule, gelling agent, pill, tincture, decoction,
Infusion, spirit, liquid extract, elixir, extract, syrup, powder, aromatic waters, limonada etc..
The tablet can be for example, sugar coated tablet, film coating piece, Enteric coated tablets, oral tablet, sublingual tablet, buccal tablet, nozzle
Chew the form of piece, dispersible tablet, multilayer tablet, compression coated tablets, effervescent tablet, solution piece, subcutaneous piece etc..It should be appreciated that this field
Technical staff can carry out various modifications and alterations to the tablet.
The pharmaceutic adjuvant may include additive, such as excipient, disintegrant, adhesive, lubricant, emulsifier, suspending
Agent, stabilizer etc..If desired, sweetener and/or flavoring agent can also be added.For tablet, can be typically added to medicinal auxiliary
Expect such as lactose and cornstarch and lubricant such as magnesium stearate etc..For capsule, lactose and/or anhydrous can be used
Cornstarch can also include liquid-carrier (such as polyethylene glycol or fatty acid oil) as diluent.It, can for waterborne liquid
By active constituent and emulsifier and/or suspending agent formulated in combination.If desired, specific sweetener and/or seasoning can be added
Agent.Syrup can include as the sucrose of sweetener, specific preservative, dyestuff, colorant and/or corrigent.It is preparing
Additive used in these various preparations should be that pharmacy is pure and nontoxic.
Below by the statistics of patient's premature ejaculation therapeutic effect in each embodiment, the invention will be further described.It is counted
The condition of patient is as follows：（1）There is penis and is inserted into before vagina or is inserted into the 2 of vagina at least 75% or more sexual intercourse in patient
There is a situation where ejaculate within minute；
（2）Male；
（3）Age 18-65 Sui；
（4）Patient can at least keep stable sexual intercourse in 6 months during treatment with the opposite sex；
（5）Occurs premature ejaculation before the treatment at least 3 months；
（6）There is no history of disease or any physical examination exception, laboratory examination abnormal, imageological examination exception and electrocardiogram
Check the people of abnormal health；
（7）Patient willingness stops other types of conventional therapy, including drug, behaviour therapy or local treatment.
The SS of therapeutic effect is as shown in table 1：
Table 1
| Therapeutic effect | Therapeutic effect describes |
| In vain | Than original time lengthening less than 5min |
| Effectively | Than original 5~15min of time lengthening |
| It is effective | Than original 15~30min of time lengthening |
| It cures | Than original time lengthening 30min or more, 3 months are discontinued without recurrence |
Embodiment 1
When the unit dosage forms that patient takes orally described pharmaceutical composition are Pargyline 1mg, Prozac 10mg, 2 times/day；When showing
After imitating effect, continuing medication, medicining times are changed to 1 times/day after half a month；Another week medication dosage form is changed to Pargyline 0.5mg, fluorine west
Spit of fland 5mg, 1 times/day；Another week medicining times be changed to 1 time/next day, another week complete withdrawal.Final therapeutic effect statistics is such as
Shown in table 2：
Table 2
Embodiment 2
When the unit dosage forms that patient takes orally described pharmaceutical composition are Pargyline 2mg, Prozac 10mg, 2 times/day；When showing
After imitating effect, continuing medication, medicining times are changed to 1 times/day after half a month；Another week medication dosage form is changed to Pargyline 1mg, Prozac
5mg, 1 times/day；Another week medicining times be changed to 1 time/next day, another week complete withdrawal.Final therapeutic effect statistics such as table
Shown in 3：
Table 3
Embodiment 3
When the unit dosage forms that patient takes orally described pharmaceutical composition are Pargyline 10mg, Prozac 10mg, 2 times/day；When showing
After imitating effect, continuing medication, medicining times are changed to 1 times/day after half a month；Another week medication dosage form is changed to Pargyline 5mg, Prozac
5mg, 1 times/day；Another week medicining times be changed to 1 time/next day, another week complete withdrawal.Final therapeutic effect statistics such as table
Shown in 4：
Table 4
Embodiment 4
When the unit dosage forms that patient takes orally described pharmaceutical composition are Pargyline 10mg, Prozac 2mg, 2 times/day；When showing
After imitating effect, continuing medication, medicining times are changed to 1 times/day after half a month；Another week medication dosage form is changed to Pargyline 5mg, Prozac
1mg, 1 times/day；Another week medicining times be changed to 1 time/next day, another week complete withdrawal.Final therapeutic effect statistics such as table
Shown in 5：
Table 5
Embodiment 5
When the unit dosage forms that patient takes orally described pharmaceutical composition are Pargyline 10mg, Prozac 1mg, 2 times/day；When showing
After imitating effect, continuing medication, medicining times are changed to 1 times/day after half a month；Another week medication dosage form is changed to Pargyline 5mg, Prozac
0.5mg, 1 times/day；Another week medicining times be changed to 1 time/next day, another week complete withdrawal.Final therapeutic effect statistics is such as
Shown in table 6：
Table 6
The active constituent pa that the pharmaceutical composition that can be seen that the treatment premature ejaculation from the statistical result of above-described embodiment includes is lucky
Woods, Prozac use different weight ratios or different unit dosage forms, and certain therapeutic effect can be obtained to treatment premature ejaculation,
In especially with weight ratio be 1:1, unit dosage forms are that the obtained therapeutic effect of Pargyline 10mg, Prozac 10mg is best.
Due to Pargyline of the present invention, Prozac is relatively low with respect to the price of Dapoxetine hydrochloride, therefore the present invention can
Medical treatment cost is reduced, patient burden is mitigated；The present invention will not make patient generate serotonin syndrome, therefore side effect reduces；
Present invention proportioning is reasonable, prepares simply, is conducive to industrialized production；The present invention can treat prospermia of males symptom, extend male's property
Life-time.
It should be understood that above-described embodiment is only used for that those skilled in the art is made to more fully understand the present invention, it cannot
For limiting the scope of the invention, those skilled in the art can carry out various modification and transformations to the present invention, these
It falls within the protection domain limited such as the claim.
Claims (10)
1. treating the pharmaceutical composition of premature ejaculation, which is characterized in that it include as the Pargyline of active constituent or its officinal salt,
Prozac or its officinal salt, wherein the Pargyline or its officinal salt, Prozac or its officinal salt weight ratio be
0.1:10~10:0.1.
2. the pharmaceutical composition for the treatment of premature ejaculation according to claim 1, which is characterized in that the Pargyline or its is pharmaceutically acceptable
The weight ratio of salt, Prozac or its officinal salt is 1:10~10:1.
3. the pharmaceutical composition for the treatment of premature ejaculation according to claim 1, which is characterized in that the Pargyline or its is pharmaceutically acceptable
The weight ratio of salt, Prozac or its officinal salt is 1:1.
4. the pharmaceutical composition for the treatment of premature ejaculation according to any one of claims 1 to 3, which is characterized in that described pharmaceutically acceptable
Salt is hydrochloride.
5. the pharmaceutical composition for the treatment of premature ejaculation according to claim 4, which is characterized in that further include optional medicinal auxiliary
Material.
6. the pharmaceutical composition for the treatment of premature ejaculation according to claim 5, which is characterized in that the pharmaceutic adjuvant includes figuration
Agent, disintegrant, adhesive, lubricant, emulsifier, suspending agent, stabilizer, sweetener, flavoring agent.
7. the pharmaceutical composition for the treatment of premature ejaculation according to claim 6, which is characterized in that described pharmaceutical composition is oral
Preparation, including tablet, capsule, granule, pill.
8. the pharmaceutical composition for the treatment of premature ejaculation according to claim 7, which is characterized in that the unit dose of the oral preparation
Type includes the Prozac of the Pargyline of 0.1~10mg, 0.1~10mg.
9. the pharmaceutical composition for the treatment of premature ejaculation according to claim 7, which is characterized in that the unit dose of the oral preparation
Type includes the Prozac of the Pargyline of 1~10mg, 1~10mg.
10. the pharmaceutical composition for the treatment of premature ejaculation according to claim 7, which is characterized in that the unit of the oral preparation
Dosage form includes the Prozac of the Pargyline of 10mg, 10mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710152275.0A CN108619122A (en) | 2017-03-15 | 2017-03-15 | Treat the pharmaceutical composition of premature ejaculation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710152275.0A CN108619122A (en) | 2017-03-15 | 2017-03-15 | Treat the pharmaceutical composition of premature ejaculation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108619122A true CN108619122A (en) | 2018-10-09 |
Family
ID=63686380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710152275.0A Pending CN108619122A (en) | 2017-03-15 | 2017-03-15 | Treat the pharmaceutical composition of premature ejaculation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108619122A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179988A (en) * | 2019-07-10 | 2019-08-30 | 王大伟 | Serotonin reuptake inhibitors and monoamine oxidase inhibitors combine the application in preparation treatment depression or premature ejaculation drug |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020161016A1 (en) * | 2000-11-21 | 2002-10-31 | Peter Tam | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation |
| CN1852704A (en) * | 2003-07-11 | 2006-10-25 | 世界Pe专利霍德科有限公司 | Treatment of premature ejaculation |
| CN102036669A (en) * | 2008-05-19 | 2011-04-27 | 株式会社柳韩洋行 | Pharmaceutical composition for the treatment of premature ejaculation |
-
2017
- 2017-03-15 CN CN201710152275.0A patent/CN108619122A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020161016A1 (en) * | 2000-11-21 | 2002-10-31 | Peter Tam | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation |
| CN1852704A (en) * | 2003-07-11 | 2006-10-25 | 世界Pe专利霍德科有限公司 | Treatment of premature ejaculation |
| CN102036669A (en) * | 2008-05-19 | 2011-04-27 | 株式会社柳韩洋行 | Pharmaceutical composition for the treatment of premature ejaculation |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179988A (en) * | 2019-07-10 | 2019-08-30 | 王大伟 | Serotonin reuptake inhibitors and monoamine oxidase inhibitors combine the application in preparation treatment depression or premature ejaculation drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131598A5 (en) | ||
| US20220193052A1 (en) | Liquid pharmaceutical composition | |
| US9314444B2 (en) | Composition and method for treatment of NASH | |
| EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
| KR101298348B1 (en) | A pharmaceutical composition for the treatment of premature ejaculation | |
| WO2022123074A1 (en) | Liquid apixaban formulation in small dose volume | |
| CN108619122A (en) | Treat the pharmaceutical composition of premature ejaculation | |
| CN108619146A (en) | A kind of pharmaceutical composition for treating premature ejaculation | |
| EP1884241B1 (en) | A oral preparation comprising dyclonine hydrochloride | |
| JP5211677B2 (en) | Oral solution | |
| US20060094760A1 (en) | Composition, system and method of treatment of gastrointestinal disorders with nizatidine oral solution | |
| AU2012276476B2 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| US10213437B2 (en) | Pharmaceutical preparation for masked taste oral administration, containing clomipramine | |
| JPWO2016121147A1 (en) | Enema | |
| JP6856813B1 (en) | Zinc Intravenous Infusion Formulation | |
| JP2006008540A (en) | Cold remedy | |
| JP2007145731A (en) | Pharmaceutical preparation for oral administration having stegnotic effect | |
| KR20150144209A (en) | Pharmaceutical composition comprising stabilized desmopressin or pharmaceutically acceptable salt thereof | |
| Fozard et al. | A controlled clinical trial of oral droperidol and droperidol plus diazepam for premedication in children | |
| WO2023183153A1 (en) | Combination nasal and oral therapy for weight loss | |
| US20090209503A1 (en) | Colonic delivery therapeutic agents for inflammatory bowel disease | |
| RU2540509C1 (en) | Drug | |
| JP2020532564A (en) | Calcium supplementation composition | |
| WO2011058982A1 (en) | Therapeutic agent for gastrointestinal diseases | |
| EA028400B1 (en) | Method of preventing and treating obesity and overweight and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |
|
| RJ01 | Rejection of invention patent application after publication |